Latest / The Buyout Show with Fexingo: Private Equity, Roll-Ups, and Business Acquisitions / How Private Equity Is Rolling Up Veterinary Emergency Hospitals
Transcript
- Lucas: So you take your dog to the emergency vet at two in the morning because she ate something she shouldn't have. The bill comes out to about four thousand dollars. You pay it because you have to. And that transaction, at scale, has become one of the most attractive annuity streams in private equity right now. Luna: I'm guessing this isn't just about the one-off emergency visit. It's about building a network of those hospitals, right? Lucas: Exactly. The segment we're talking about today is emergency and specialty veterinary hospitals — the 24-hour ERs, the oncology centers, the neurology and surgery referral practices. These are not your neighborhood general practice vet. They are high-acuity, high-revenue facilities that can generate anywhere from five million to twenty million dollars in annual revenue per location. Luna: And private equity has noticed. Big time. Lucas: Big time. The poster child for this roll-up is Ethos Veterinary Health. Ethos was formed in 2017 when JAB Investors — the same JAB behind Panera Bread, Caribou Coffee, and a massive pet care portfolio that includes J.M. Smucker's pet food business — decided to consolidate emergency vet hospitals under one roof. They started with a handful of locations in New England. Today, Ethos owns over one hundred emergency and specialty hospitals across the US. Luna: That's a lot of ERs. What's the pitch to the individual practice owner who's been running their own shop for twenty years? Lucas: The pitch is pretty standard for a PE roll-up. You get an upfront payout, usually between four and seven times EBITDA. You stay on as a salaried medical director, often with an equity stub in the larger platform. You get access to capital for new equipment — CT scanners, MRIs, linear accelerators for radiation oncology — that you could never afford on your own. And you get centralised back-office support for billing, HR, and supply chain. Luna: But the trade-off is that you lose control over pricing, staffing, and how many cases you take on each night. Lucas: That's the tension. And it's where the economics get interesting. An independent emergency vet might see thirty cases a night. After the roll-up, the same hospital might be pushed to see forty-five or fifty. The revenue per case is going up, too, because the new corporate fee schedule is higher. One study from the Veterinary Hospital Managers Association found that emergency fees at corporately owned hospitals are twelve to eighteen percent higher than at independents. Luna: And the argument is that you're getting better care because of the equipment and the specialists on call. But is that actually what happens? Lucas: It's complicated. On one hand, yes — a hospital with a board-certified emergency veterinarian and an on-call surgeon is objectively more capable than a solo vet with a stethoscope. But the staffing challenge in veterinary medicine is brutal right now. There are about seventy-five hundred boarded emergency veterinarians in the entire United States. That's not enough to staff every 24-hour ER that PE wants to acquire. So you end up with hospitals that are technically part of a network but can't actually offer 24-hour coverage because they can't hire the doctors. Luna: So you've got a brand that promises specialty care, but the customer — the pet owner — might still wait six hours in the lobby. Sounds familiar, actually. Lucas: Yeah, it echoes what happened in human emergency medicine when private equity consolidated hospitalist groups. But there's a structural difference in vet med that makes the roll-up even more attractive to PE: the payment model. In human healthcare, you deal with insurance companies, Medicare, all sorts of reimbursement complexity. In veterinary medicine, it's almost entirely cash — or credit card — at the point of service. You provide the care, you collect the money, there's no billing cycle. Luna: That's a huge advantage. No denials, no prior authorizations. Just swipe the card. Lucas: And that cash flow is very predictable. The average emergency visit runs between eight hundred and two thousand dollars, but a single overnight stay with surgery can easily hit ten to fifteen thousand. And because people are emotionally attached to their pets, they are extremely price-inelastic. The demand doesn't go down when you raise prices. Luna: Which is exactly why PE loves it. Let's talk about the numbers. What does a typical acquisition look like for a platform like Ethos? Lucas: A single well-run emergency hospital with, say, twelve million in revenue and EBITDA margins around twenty-five percent — that's three million in cash flow. A PE firm might pay five and a half times that, so about sixteen to seventeen million dollars. They finance the deal with about sixty percent debt, put in thirty to forty percent equity, and then they look for ways to grow revenue by fifteen percent a year. At that rate, they can double their invested equity in about three to four years. Luna: And the debt is often structured through a real estate investment trust, right? Because many of these hospitals own their buildings. Lucas: Good catch. That's become a common play. The PE firm buys the hospital's real estate and the business separately. The real estate goes into a REIT that charges rent to the operating company. That rent is tax-deductible for the operator, and the REIT pays no corporate tax if it distributes ninety percent of income to shareholders. It's a double tax arbitrage that effectively boosts the after-tax return on the deal by two to three hundred basis points. Luna: So the building itself becomes a profit center, separate from the medicine. Lucas: Exactly. And that's one of the reasons these roll-ups can pay such high multiples. The acquiring platform isn't just buying the cash flow of the practice — they're buying a real estate asset that can be refinanced or sold later. But there's a risk that I think gets overlooked. When you separate the real estate from the operating business, the hospital operator is now a tenant. If the business hits a rough patch — say, a recession reduces pet spending — they still have to pay the rent. And the rent is usually set at a rate that assumes continued growth. Luna: Meaning the operator could get squeezed. Which actually happened in the auto body repair roll-ups we covered earlier. Lucas: Exactly the same dynamic. The other elephant in the room is the veterinary school pipeline. There are only thirty-three accredited veterinary schools in the US, and they graduate about thirty-five hundred new veterinarians each year. Of those, only a fraction go into emergency medicine. The demand for emergency vets is growing at about eight percent a year, but supply is growing at maybe two percent. So wages for emergency vets have been rising twelve to fifteen percent annually for the last five years. Luna: Which eats directly into the EBITDA margins that PE is banking on. Lucas: It does. And that's the central tension in the thesis. The roll-up works beautifully on paper as long as you can keep staffing costs under control. But if you have to pay a signing bonus of fifty thousand dollars to recruit a boarded emergency vet, and then you're paying them two hundred thousand a year — plus production bonuses — your cost structure changes. Some of these platforms have seen EBITDA margins compress from the mid-twenties down to the mid-teens over the past two years. Luna: So the playbook might be running into a wall. Is the market starting to price that in? Lucas: There are signs. Ethos and its main competitor, MedVet, which is owned by the PE firm OMERS, have both slowed their acquisition pace in the last twelve months. Multiples that were six to seven times EBITDA two years ago have come down to four and a half or five times. And we're starting to see a few platforms put themselves up for sale, looking for an exit. But there's still a lot of capital chasing deals. The pet care sector overall is a thirty-billion-dollar addressable market, and emergency and specialty is the highest-margin slice of it. Luna: So what does this mean for the average pet owner? If I walk into an Ethos hospital in 2026, what's different from five years ago? Lucas: The most noticeable change is probably the estimate. They will hand you a much more detailed, itemized estimate before they do anything. That's partly good — transparency — but it also creates a moment of sticker shock that's more intense than it used to be. You'll also see more pressure to purchase pet insurance at the front desk. Some Ethos hospitals now have a tablet where you can sign up for a policy before you see the doctor. Luna: Which, to be fair, is probably a good idea for the owner. But it also reduces the price sensitivity for the hospital. Lucas: Exactly. If insurance pays, the hospital can charge more without the owner feeling it directly. That's one of the strategic reasons PE likes pet insurance, too — many of these firms have investments on both sides. JAB, for instance, owns a pet insurance company called Pet Partners. So you've got vertical integration: the insurance company pays the hospital, and the hospital pays rent to the REIT. It's all in the family. Luna: It's a pretty closed loop. And the regulatory environment is basically silent on all of this. There's no FTC challenge to these roll-ups because the market is still fragmented — no single platform has more than five percent national share. Lucas: That's the loophole. You can buy up hundreds of hospitals and never trigger a monopoly review as long as your market share in any given metropolitan area stays below a certain threshold. But in cities like Boston, Denver, or Austin, Ethos or MedVet might control forty percent of the emergency capacity. And that's where you see the pricing power get exercised. Luna: And that's where the conversation about pet care affordability starts to sound a lot like the conversation about human healthcare affordability. Lucas: Right. And that's the thing that gives me pause. Veterinary medicine has always been a cash business, and it's always been expensive for certain procedures. But the consolidation wave is making it more expensive, faster. And the pet owner doesn't have a union or an employer-sponsored plan to negotiate on their behalf. They're just standing at the counter with a credit card and a sick animal. Luna: And if these conversations have moved your thinking about your own business or your own investing, that's the kind of thing we hear from listeners pretty often. And honestly, it's what keeps this show going — the fact that people find this stuff useful in their actual work. Lucas: That's true. And we keep it ad-free because of that. If you've gotten something out of these episodes and you want to make sure we keep doing them, there's a simple way to support the show — buy me a coffee dot com slash fexingo. It's not a subscription, no pressure at all. Just a way for listeners who find value here to help cover the production costs. Luna: Yeah, exactly. Every bit helps, and it all goes straight into making this better. So if that's something you're inclined to do, we appreciate it. Lucas: Anyway, back to the veterinary roll-up. I think the key question for the next two years is whether the platforms can actually deliver the staffing to make the 24-hour promise real. If they can't, the brand premium erodes. And if the brand premium erodes, the multiples compress further, and the exit gets harder. Luna: So it's not just about buying practices. It's about whether you can actually run them at a higher level than the previous owner could. Lucas: Exactly. And that's the test that a lot of these roll-ups are about to face. The easy part is signing the deal. The hard part is making the medicine better while keeping the margins intact.